Monogenic forms of common variable immunodeficiency and implications on target therapeutic approaches.
Journal
Current opinion in allergy and clinical immunology
ISSN: 1473-6322
Titre abrégé: Curr Opin Allergy Clin Immunol
Pays: United States
ID NLM: 100936359
Informations de publication
Date de publication:
01 Dec 2023
01 Dec 2023
Historique:
medline:
6
11
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
ppublish
Résumé
Common variable immunodeficiency (CVID) is the most common symptomatic inborn error of immunity. The disorder is characterized by variable clinical and immunological manifestations, and, in a small minority of patients, a monogenic cause may be identified. In this review, we focalized on three different monogenic forms of CVID-like disease. Activated phosphoinositide 3-kinase delta syndrome (APDS) is a rare disorder characterized by hyperactivated class I phosphatidylinositol-3 kinase (PI3K) pathway. Affected patients present with respiratory infectious episodes, impaired viral clearance and lymphoproliferation. Recently, a direct PI3K inhibitor has been approved and it showed encouraging results both in controlling clinical and immunological manifestations of the disease. On the other hand, patients with defects in CTLA-4 or LRBA gene present with life-threatening immune dysregulation, autoimmunity and lymphocytic infiltration of multiple organs. Abatacept, a soluble cytotoxic T lymphocyte antigen 4 (CTLA-4) fusion protein that acts as a costimulation modulator, has been widely implemented for affected patients with good results as bridge treatment. Understanding the biological basis of CVID is important not only for enriching our knowledge of the human immune system, but also for setting the basis for potential targeted treatments in this disorder.
Identifiants
pubmed: 37767915
doi: 10.1097/ACI.0000000000000947
pii: 00130832-990000000-00086
pmc: PMC10621638
doi:
Substances chimiques
CTLA-4 Antigen
0
Phosphatidylinositol 3-Kinases
EC 2.7.1.-
LRBA protein, human
EC 2.7.10.-
Adaptor Proteins, Signal Transducing
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
461-466Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
J Allergy Clin Immunol. 2023 Oct;152(4):984-996.e10
pubmed: 37390899
Curr Opin Immunol. 2021 Oct;72:176-185
pubmed: 34153571
Drugs. 2023 Jul;83(10):943-948
pubmed: 37256490
J Exp Med. 2018 Aug 6;215(8):2073-2095
pubmed: 30018075
J Allergy Clin Immunol. 2017 Feb;139(2):597-606.e4
pubmed: 27555459
Biomed J. 2021 Aug;44(4):400-411
pubmed: 34384744
Expert Rev Clin Immunol. 2023 Jun;19(6):627-638
pubmed: 36996348
Front Immunol. 2018 Mar 16;9:543
pubmed: 29599784
J Allergy Clin Immunol. 2022 Feb;149(2):736-746
pubmed: 34111452
Science. 2013 Nov 15;342(6160):866-71
pubmed: 24136356
Front Immunol. 2022 Dec 27;13:1070068
pubmed: 36636328
J Allergy Clin Immunol. 2018 Feb;141(2):770-775.e1
pubmed: 28502825
J Allergy Clin Immunol. 2019 Jan;143(1):266-275
pubmed: 29778502
J Exp Med. 2023 Jul 3;220(7):
pubmed: 37042938
Clin Immunol. 2021 Aug;229:108779
pubmed: 34116213
Front Immunol. 2021 Dec 17;12:786516
pubmed: 34975878
Front Immunol. 2018 May 14;9:636
pubmed: 29867916
J Exp Med. 2020 Feb 3;217(2):
pubmed: 31841125
J Clin Invest. 2014 Sep;124(9):3923-8
pubmed: 25133428
Front Pediatr. 2021 Apr 28;9:662645
pubmed: 33996698
Pulm Pharmacol Ther. 2023 Apr;79:102201
pubmed: 36841351
J Allergy Clin Immunol. 2016 Jul;138(1):210-218.e9
pubmed: 27221134
J Allergy Clin Immunol Pract. 2019 Sep - Oct;7(7):2379-2386.e5
pubmed: 30995531
J Clin Med. 2020 Oct 17;9(10):
pubmed: 33080915
Medicine (Baltimore). 2023 Feb 3;102(5):e32816
pubmed: 36749229
Blood. 2020 Feb 27;135(9):656-667
pubmed: 31942606
Am J Hum Genet. 2012 Jun 8;90(6):986-1001
pubmed: 22608502
J Allergy Clin Immunol. 2020 May;145(5):1452-1463
pubmed: 31887391
Blood. 2023 Mar 2;141(9):971-983
pubmed: 36399712
Science. 2014 Sep 26;345(6204):1623-1627
pubmed: 25213377
Cell Rep. 2021 Oct 12;37(2):109804
pubmed: 34644563
Allergy. 2022 Oct;77(10):3108-3123
pubmed: 35491430
J Autoimmun. 2019 Jul;101:145-152
pubmed: 31054942
Blood. 2022 Jan 13;139(2):300-304
pubmed: 34714911
J Allergy Clin Immunol Pract. 2021 Nov;9(11):4095-4102
pubmed: 34352450
Science. 2015 Jul 24;349(6246):436-40
pubmed: 26206937
Clin Immunol. 2020 Nov;220:108589
pubmed: 32927079
Front Immunol. 2022 Nov 02;13:1011646
pubmed: 36405723
Sci Transl Med. 2022 Oct 26;14(668):eabn5811
pubmed: 36288278
J Allergy Clin Immunol. 2022 Jan;149(1):410-421.e7
pubmed: 34033842
Front Immunol. 2022 Feb 17;13:742530
pubmed: 35250968
J Exp Med. 2014 Dec 15;211(13):2537-47
pubmed: 25488983
Adv Biol Regul. 2020 Jan;75:100657
pubmed: 31611073
Contemp Clin Trials Commun. 2022 Sep 24;30:101008
pubmed: 36262801
Immunol Med. 2023 May 13;:1-5
pubmed: 37178059
J Clin Immunol. 2022 Oct;42(7):1473-1507
pubmed: 35748970
J Allergy Clin Immunol. 2019 Jul;144(1):236-253
pubmed: 30738173
Nat Immunol. 2014 Jan;15(1):88-97
pubmed: 24165795
J Allergy Clin Immunol Pract. 2019 Nov - Dec;7(8):2790-2800.e15
pubmed: 31238161
J Allergy Clin Immunol Pract. 2016 Jan-Feb;4(1):38-59
pubmed: 26563668
J Clin Immunol. 2022 May;42(4):837-850
pubmed: 35296988
Clin Rev Allergy Immunol. 2020 Dec;59(3):323-333
pubmed: 31111319
J Allergy Clin Immunol. 2018 Dec;142(6):1932-1946
pubmed: 29729943
J Allergy Clin Immunol. 2016 Aug;138(2):615-619.e1
pubmed: 27102614
Immunity. 2019 Apr 16;50(4):1084-1098.e10
pubmed: 30926234